Fidaxomicin + Vancomycin & Clostridioides difficile infection (CDI) (recurrent)

There is no FDA or EMA approval for the use of Fidaxomicin + Vancomycin as a combination therapy for Clostridioides difficile infection (CDI) (recurrent). Both Fidaxomicin and Vancomycin are individually approved by the FDA and EMA for the treatment of CDI, including recurrent cases, but neither agency has approved their simultaneous use as a fixed combination or sequential therapy for this indication.
Bishop & Tiruvoipati 2022 J Antimicrob Chemother 78(1): 21-30
Pettit et al. 2024 Infect Control Hosp Epidemiol 45(11): 1-7

see also:
Antibiotics & Clostridioides difficile infection (CDI) (recurrent)
Fidaxomicin & Clostridioides difficile infection (CDI) (initial)
Fidaxomicin & Clostridioides difficile infection (CDI) (recurrent)
Vancomycin & Clostridioides difficile infection (CDI) (initial)
Vancomycin & Clostridioides difficile infection (CDI)